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STUDY QUESTION: Are exosomal microRNAs (miRNAs) in seminal plasma (SP) useful as markers of the origin of azoospermia and the
presence of sperm in the testis?
SUMMARY ANSWER: Our study demonstrated the potential of several miRNAs contained in small extracellular vesicles (sEVs) of seminal
fluid as sensitive and specific biomarkers for selecting those azoospermic individuals with real chances of obtaining spermatozoa from the tes-
ticular biopsy.
WHAT IS KNOWN ALREADY: There are no precise non-invasive diagnostic methods for classifying the origin of the sperm defects in
semen and the spermatogenic reserve of the testis in those infertile men with a total absence of sperm in the ejaculate (azoospermia). The
diagnosis of such individuals is often based on the practice of biopsies. In this context it is reasonable to study the presence of organ-specific
markers in human semen that contains fluid from the testis and the male reproductive glands, which could help in the diagnosis and prognosis
of male infertility. Additionally, seminal fluid contains high concentrations of sEVs that are morphologically and molecularly consistent with
exosomes, which originate from multiple cellular sources in the male reproductive tract.
STUDY DESIGN, SIZE, DURATION: A case and control prospective study was performed. This study compares the miRNA content of
exosomes in semen samples obtained from nine normozoospermic fertile individuals (control group), 14 infertile men diagnosed with azoo-
spermia due to spermatogenic failure, and 13 individuals with obstructive azoospermia and conserved spermatogenesis. Additionally, three
severe oligozoospermic individuals (<5 × 106 sperm/ml) were included in the study.
PARTICIPANTS/MATERIALS, SETTING, METHODS: A differential high-throughput miRNA profiling analysis using miRNA quanti-
tative PCR panels was performed in SP exosomes from azoospermic patients and fertile individuals.
MAIN RESULTS AND THE ROLE OF CHANCE: A total of 623 miRNAs were included in the miRNA profiling stage of the study. A
total of 397 miRNAs (63.7%) were consistently detected in samples from all groups and statistically analysed, which revealed altered patterns
of miRNA expression in infertile patients. We focused on the miRNAs that were differentially expressed between azoospermia as a result of
an obstruction in the genital tract (i.e. having conserved spermatogenesis) and azoospermia caused by spermatogenic failure, and described,
in a miRNA validation stage of the study, the expression values of one miRNA (miR-31-5p) in exosomes from semen as a predictive bio-
marker test for the origin of azoospermia with high sensitivity and specificity (>90%). The efficacy of the predictive test was even better when
the blood FSH values were included in the analysis. Furthermore a model that included miR-539-5p and miR-941 expression values is also
described as being useful for predicting the presence of residual spermatogenesis in individuals with severe spermatogenic disorders with diag-
nostic accuracy.
© The Author(s) 2018. Published by Oxford University Press on behalf of the European Society of Human Reproduction and Embryology.
This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/), which permits
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LIMITATIONS, REASONS FOR CAUTION: Further studies, with an independent second population involving a larger number of sam-
ples, are needed to confirm our findings.
WIDER IMPLICATIONS OF THE FINDINGS: Our findings contribute to the search for the most valuable genetic markers that are
potentially useful as tools for predicting the presence of testicular sperm in azoospermic individuals.
STUDY FUNDING/COMPETING INTEREST(S): This work was financially supported by grants from the Fondo de Investigaciones
Sanitarias/Fondo Europeo de Desarrollo Regional “Una manera de hacer Europa” (FIS/FEDER) [Grant number PI15/00153], the Generalitat
de Catalunya [Grant number 2014SGR5412]. S.L. is sponsored by the Researchers Stabilization Program (ISCIII/Generalitat de Catalunya)
from the Spanish National Health System [CES09/020].
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Introduction
Approximately 4% of men worldwide suffer from infertility. In a high
percentage of those men, the aetiology of infertility is closely related to
alterations of the classic parameters of basic semen analysis, such as
the concentration, motility and/or morphology of the spermatozoa
(Guzick et al., 2001). Routine biochemical markers in semen, such as
acid phosphatase, citric acid and zinc (prostate), fructose (seminal vesi-
cles) and alpha-glucosidase (epididymis), are used to diagnose possible
acquired and congenital obstructions or to identify functional abnor-
malities of the genital glands such as those that occur after infection or
inflammation. Although still useful, these biochemical markers have
limited clinical utility for classifying the origin of the sperm defects in
semen, and the spermatogenic reserve of the testis in those men with
a total absence of sperm in the ejaculate (azoospermia), a particularly
challenging condition which accounts for more than 10% cases of male
infertility (Tüttelmann and Nieschlag, 2010). There are no precise
non-invasive diagnostic methods for determining such conditions, and
in general the diagnosis is based on the practice of biopsies. In this con-
text it is reasonable to study the presence of organ-specific markers in
human fluids that could help in the diagnosis and prognosis of azoo-
spermia. Semen, a complex fluid composed of cells and seminal plasma
(SP), can be accessed with relative ease. The SP, which contains fluid
from the testis and the male reproductive glands, is emerging as a
source for potential biomarkers for reproductive diseases.
Several studies have shown that SP contains high concentrations of
small extracellular vesicles (sEVs), that are morphologically and
molecularly consistent with exosomes, which originate from multiple
cellular sources in the male reproductive tract: namely prostate (pros-
tasomes), epididymis (epididymosomes), seminal vesicles and the
testis (Renneberg et al., 1997; Vojtech et al., 2014). Exosomes are cell-
derived vesicles present in various biological fluids. It has been calcu-
lated that, in mammals, each ejaculate contains trillions of exosomes,
characterized by a high content in cholesterol and sphingomyelin, and
a very complex protein composition. Exosomes have immunosuppres-
sive effects on the cells, which is relevant in the genital mucosa. The
exosomes also contain coding and non-coding RNAs (Valadi et al.,
2007) that can be transferred to recipient cells to modulate their func-
tion, thus mediating paracrine signalling (Valadi et al., 2007; Zomer
et al., 2010). In particular, in male fertility the semen exosomes have
been proposed as participating in the capacitation and acrosome reac-
tion of sperm (Aalberts et al., 2013) and as functioning as a means of
selectively transporting and delivering various regulatory molecules to
the female reproductive system, thus contributing to fertilization
(Vojtech et al., 2014).
Exosomes in semen contain a population of small non-coding RNAs
(sncRNAs; from 20 to 100 nucleotides), including microRNAs
(miRNAs) (21%), and several other RNAs such as Piwi-interacting
RNAs (piRNAs), Y RNAs, rRNAs and tRNAs (Vojtech et al., 2014).
Semen exosomes show a unique profile of miRNAs that greatly differs
from that of other biological fluids (Vojtech et al., 2014). It seems that
the content of RNA, and in particular of the miRNA, of the exosomes
in semen varies according to the cell of origin of the sEVs, so it is able
to reflect the pathophysiological conditions of the organ of origin. This
fact is relevant when considering expression profiles of miRNAs in
exosomes as potentially reliable biomarkers.
MiRNAs (19–22 nucleotides) negatively modulate gene expression
at the post-transcriptional level, affecting mRNA stability and transla-
tion. Studies have shown that miRNAs play critical roles in a variety of
biological processes such as cell proliferation, differentiation, apoptosis
and carcinogenesis (Bartel, 2004; He and Hannon, 2004). miRNAs
actively participate in diverse aspects of vertebrate differentiation and
development (Lakshmipathy et al., 2007; Tang et al., 2007; Hammond,
2015), and, specifically, in testis differentiation in the embryo, male
germline development and sperm production (Ro et al., 2007; Hayashi
et al., 2008; Maatouk et al., 2008; Bouhallier et al., 2010). miRNAs are
not only present in cells but also in extracellular milieu, especially in dif-
ferent biofluids including not only blood plasma (Arroyo et al., 2011),
but also saliva, tears, urine, breast milk, colostrum, peritoneal fluid,
cerebrospinal fluid, bronchial lavage and, strikingly, seminal fluid
(Weber et al., 2010). Such extracellular miRNAs are presented either
bound with protein complexes (Li et al., 2012) or contained in EVs
such as the exosomes (Valadi et al., 2007). This attribute allows
miRNAs to be remarkably resistant to the presence of high RNAse
activity in the extracellular environment. Consequently, miRNAs in
human fluids have been postulated as useful non-invasive biomarkers
for human diseases.
The mRNAs and the miRNAs of SP that come from the testis or
from the epididymis are hardly detectable in the blood, as they are
contained in vesicles or bound to protein complexes and cannot cross
the blood-testicular or hematoepididimary barriers. Studying them in
SP would therefore seem to be a valuable approach but few studies
have analysed the expression profile of miRNAs contained in the exo-
somes of the semen biofluid.
Our research group proposed the study of expression levels of exo-
some miRNAs in semen from men with severe spermatogenic
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disorders and vasectomized men to evaluate their use as non-invasive
biomarkers that may contribute to the diagnosis of azoospermia.
Additionally, it would help to describe the miRNAs contained in exo-
somes that come from testis and epididymis, as semen from vasecto-
mized men does not contain secretions from these two organs.
Furthermore, miRNAs derived from/associated with the presence of
the germline would be identified when studying semen from men with
deficient sperm production. The use of non-invasive biomarkers in
azoospermia would help in determining the pathophysiological cause
of the absence of sperm in semen and help with predicting the pres-




Patients and controls participating in the study were selected from men
referred to the Andrology Service of the Fundació Puigvert. The study was
approved by the Institutional Review Board of the Centre and all the parti-
cipants signed a written informed consent.
Semen samples were obtained from nine normozoospermic (Nz) fertile
individuals consulting for vasectomy (control group); 14 infertile men diag-
nosed with secretory azoospermia (SA) (no sperm in semen sample due
to spermatogenic failure) or cryptozoospermia (<0.15 × 106 sperm/ml);
and 13 individuals with obstructive azoospermia (OA) and conserved
spermatogenesis including men successfully vasectomized (OA-V, n = 8)
and individuals presenting pathological naturally occurring obstruction in
the genital tract (OA-N, n = 5). Additionally, three severe oligozoospermic
individuals (<5 × 106 sperm/ml) were included in the study (Table I).
Semen analysis was performed on all the individuals in accordance with
World Health Organization guidelines (Cooper et al., 2010).
Men with spermatogenic disorders included in the study did not show
clinical factors (varicocele, infection, immunologic factors, anatomic mal-
formation or chemical insults) or genetic causes (chromosomal aberration
or a Y-chromosome microdeletion) for their infertility.
For the subsequent analysis of exosome miRNA levels in semen, sam-
ples were used into a two-stage (screening and validating stages) case–con-
trol designed study (Fig. 1).
Semen samples and exosome isolation
Semen samples were obtained by masturbation after 3–5 days of sexual
abstinence. They were allowed to liquefy for 30 min at 37°C. Isolation of
exosomal vesicles was performed by differential centrifugation steps
including one microfiltration step and ultracentrifugation as described else-
where (Li et al., 2012; Crescitelli et al., 2013). Briefly, cells and apoptotic
bodies were pelleted by centrifugation at 1600 g for 10 min and microvesi-
cles at 16 500 g for 10 min at 4°C to obtain SP (supernatant) which was
carefully collected and immediately stored at −80°C until use. SP (200 μl)
was filtered (0.22 μm pore size) to remove macromolecules and cell debris
that they may have still contained. Subsequently, 9 ml of PBS was addition-
ally filtered. The resulting filtrate was ultracentrifuged at 100 000 g for 2 h
at 4°C to sediment the sEVs, which mainly contain exosomes. The pellet
was resuspended in 100 μl PBS and frozen at −80°C. Nanoparticle tracking
analysis was performed by NanoSight NS300 (Malvern Instruments Ltd,
UK) showing an enrichment of particles with a size of <200 nm, accounting
for 95% of the particles recovered (Supplementary Table SI). The vesicle
distribution by size and the morphological parameters showed no signifi-
cant differences among groups.
Small RNA-containing total RNA isolation
The exosome suspension was treated with RNAse A (Qiagen NV;
Germany) (100 μg/ml final reaction concentration; 15 min at 37°C) to
degrade the residual RNA outside the vesicles.
Total RNA was obtained from exosomes using the miRCURY RNA
Isolation Kit-Cell and Plant (Exiqon; Denmark). RNA concentration was
calculated by using the QUBIT fluorometer and the Quant-iT RNA Assay
kit (Invitrogen; CA, USA). All RNA samples presented a OD 260/280 nm
ratio ≥1.7 when using a Nanodrop UV–Vis spectrophotometer (Thermo
Fisher Scientific; MA, USA).
Exosomal miRNA quantitative real-time
PCR profiling
For the miRNA screening, RNA was reverse transcribed (RT) using the
miRCURY LNA™ Universal RT miRNA PCR, Polyadenylation and cDNA
synthesis kit (Exiqon; Denmark). cDNA was diluted 50× and assayed in
10 μl PCR reactions according to the protocol for miRCURY LNA™
Universal RT miRNA PCR. Each miRNA was assayed once by quantitative
real-time PCR (qPCR) using ExiLENT SYBR Green mastermix on the
miRNA Ready-to-Use PCR Human panels I and II that include 623 mature
miRNAs of miRBase (www.mirbase.org/) in a LightCycler® 480 Instrument
(Roche; Switzerland). Experiments were conducted at Exiqon Services.
Details and conditions of analysis of the amplification curves and efficiencies
are described elsewhere (Muñoz et al., 2015).
Next, to correct for potential overall differences in amount and quality
between the samples, for each sample the raw data (Crossing points: Cp
values) were normalized to the mean of the 50 most stable assays (mean
50) that were detected in all samples: dCp = mean 50 Cp – assay Cp.
Those assays were previously selected as being the ones with the lowest
coefficient of variation (CV < 0.018) of Cp values among samples in the
study (Supplementary Table SII) as well as showing no statistical differences
in absolute expression levels between groups, either individually or for the
mean value.
The relative quantitative method of 2dCp was used to calculate the rela-
tive quantification (RQ) miRNA expression values.
Validation of miRNA candidates by RT-qPCR
analysis
First-stranded cDNA specific for miRNA was obtained by RT of 50 ng of
RNA in 10 μl, using the Universal cDNA synthesis kit II (Exiqon;
Denmark). For qPCR analysis, cDNA was diluted (12×) and assayed in
10 μl PCR reactions containing ExiLENT SYBR Green mastermix (Exiqon;
Denmark). Duplicate amplification reactions of individual assays (LNA™-
enhanced miRNA qPCR primers; Supplementary Table SIII) were carried
out on a Lightcycler® 96 Instrument (Roche; Switzerland). Target miRNA
expression for exosomes in semen samples was calculated relative to the
mean expression value of miR-30e-3p and miR-30d-5p, chosen from the
exosomal miRNA qPCR profiling study as being among the most stable
miRNAs (Supplementary Table SII). The RQ values were calculated using
the 2dCp strategy. The same procedure was applied to determine tissue
expression profiling of miRNA candidates.
Statistical analysis
The non-parametric Kruskal–Wallis test was used to analyse the differ-
ences in clinical data and absolute expression levels of reference genes.
Unpaired two-tailed Student’s t test was used to analyse the differences in
relative expression of miRNAs between groups in the miRNA profiling
study and the Benjamini–Hochberg procedure for multiple testing correc-
tion, using a maximum discovery rate of 5%, was applied to calculate the




























































1 Nz Nz 41 20, 20 nd 2.5 7.5 137 47 15 nd nd nd Yes (2) – –
2 Nz Nz 40 20, 20 nd 6.3 7.5 114 65 5 nd nd nd Yes (2) – –
3 Nz Nz 40 20, 20 nd 2.4 7.5 113 52 6 nd nd nd Yes (2) – –
4 Nz Nz 44 20, 20 nd 3.6 7.5 90 73 9 nd nd nd Yes (2) – –
5 Nz Nz 39 15, 15 nd 4.9 7.2 60 53 6 nd nd nd Yes (1) – –
6 Nz Nz 37 20, 20 nd 4.2 7.5 56 70 12 nd nd nd Yes (2) – –
7 Nz Nz 46 15, 15 nd 2.8 7.7 41 42 4 nd nd nd Yes (2) – –
8 Nz Nz 39 20, 20 nd 2.3 7.5 20 63 8 nd nd nd Yes (2) – –
9 Nz Nz 45 22, 22 nd 4.1 7.2 20 36 9 nd nd nd Yes (2) – –
10 AZO SA (Sp+) 39 6, 9 12.6 6.5 7.5 0.15 13 0 47 84 15 No – nd
11 AZO SA (Sp+) 36 17, 0 15.3 4.0 7.2 0.1 4 0 nd nd nd No No (1 IVF) R: 0.029
12 AZO SA (Sp+) 48 20, 10 17.2 2.6 7.2 0.01 0 0 nd nd nd No Gest (2 IVF) R: 0.02;
L: 0.01
13 AZO SA* (Sp+) 30 10, 9 0.4 3.8 7.7 0.001 0 0 51 48 18 No – nd
14 AZO SA* (Sp+) 22 4, 4 0.5 1.7 7.7 0.001 0 0 50 56 18 No – nd
15 AZO SA (Sp+) 51 8, 8 19.3 3.3 7.2 0-0.001 0 0 nd nd nd No – nd




17 AZO SA (Sp+) 45 15, 15 15.0 3.1 7.7 0 – – 53 39 6 No No (1 IVF) R: 0.07;
L: 0.06
18 AZO SA (Sp−) 38 10, 10 8.4 4.7 7.5 0 – – 35 73 10 No – R:0; L: 0
19 AZO SA (Sp−) 45 10, 12 55.0 5.2 7.7 0 – – nd nd nd No – R: 0; L:
0.002
20 AZO SA (Sp−) 30 9, 9 32.9 8.5 7.2 0 – – 176 167 25 No – R:0; L: 0
21 AZO SA (Sp−) 30 13, 15 18.4 5.1 7.5 0 – – 156 83 13 No – R:0; L: 0
22 AZO SA 34 12, 10 38.0 5.3 7.2 0 – – nd nd nd No – nd
23 AZO SA 32 8, 8 18.2 10.8 7.2 0 – – 161 321 23 No – nd
24 AZO OA-N# 35 20, 20 10.0 1.3 6.4 0 – – nd nd nd No – R: 0.3; L:
0.55
25 AZO OA-N# 37 25, 25 nd 0.5 6.4 0 – – nd nd nd No – R: 0.42;
L: 0.25
26 AZO OA-N 44 0, 15 8.4 2.9 7.5 0 – – 48 93 31 No No (2 IVF) L: 0.5
27 AZO OA-N 33 0, 20 6.6 4.5 7.2 0 – – 57 97 3 No – L: 0.182
28 AZO OA-N 41 20, 20 1.7 2.1 7.5 0 – – 86 69 12 No Gest (2 IVF) R: 0.246
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False Discovery Rate (FDR) for each of the P-values obtained. The
non-parametric Mann–Whitney U-test was used to evaluate differences in
relative expression of selected miRNAs between groups. Pearson product-
moment correlation coefficients (r) were calculated to determine the cor-
relation between the miRNA RQ values and the various parameters in
semen analysis or testicular biopsy in patient groups and controls.
Multivariate binary logistic regression (backward stepwise, conditional,
method) and receiver operating characteristic (ROC) curve analysis of the
RQ values was used to distinguish the aetiology of azoospermia, as well as
individuals with a positive testicular sperm extraction (TESE) value >0.01 ×
106 sperm/ml (SA_Sp+). Accuracy was measured as the area under the
ROC curve. All data analyses were performed using the SPSS software ver-
sion 15.0 (SPSS Inc.; IBM; IL, USA). A P-value ≤0.05 was considered
significant.
Results
Obstructive and secretory azoospermia show
altered profiles of miRNA contained in SP
exosomes
In order to identify global changes of the exosome miRNA levels in SP
associated with azoospermia of different origin, we first analysed the
level of expression of 623 human miRNAs in SP exosomes from three
Nz individuals (Nz; sample nos. 1,3,4) who showed normal character-
istics in a seminogram, and from azoospermic men resulting from vas-
ectomy surgical procedure (OA-V; n = 3; sample nos. 29–31) or
resulting from impaired sperm production (SA; n = 3; sample nos.
11,16,17).
No amplification values were obtained for 78 miRNAs, suggesting
that the miRNA levels were beneath the detection threshold of the
technique. Of the amplified miRNAs, 148 were excluded from further
analysis owing to poor amplification efficiency across samples (missing
expression values for six out of the nine samples). The remaining
miRNAs (n = 397; 63.7%) were further statistically evaluated and the
results are presented in Supplementary Table SIV.
The presence of 393 miRNAs (Cp value <38) was determined in
the Nz samples (two of them were not detected in OA—suggesting
that they are specifically expressed in somatic cells from epididymis or
testis—and 16 miRNAs were not expressed in either OA or SA—sug-
gesting a testicular specific expression), whereas four miRNAs were
detected in azoospermic samples but not in Nz samples, which sug-
gests that they are minor miRNAs coming from reproductive tissues
other than the epididymis and testis.
We found 60 miRNAs in OA and/or SA that presented significant
differences in expression when compared with Nz controls (Table II).
In detail, regarding the OA-Nz comparison, nine miRNAs were signifi-
cantly overexpressed (fold-change increase range: 1.47–3.70; >2-fold-
increase n = 4) and 42 underexpressed (fold-change decrease range:
1.47–1000; >2-fold-decrease n = 41). Nine of these miRNAs (eight
down-regulated and one up-regulated) passed the FDR correction (P-
value ≤ 0.0006). Fifteen out of the 42 down-regulated miRNAs (36%)
are located in chromosome X. Some of the down-regulated miRNAs
map to miRNA clusters: chromosome 19 (a non-conserved cluster)
(Bentwich et al., 2005), and chromosome X (four clusters) (www.
mirbase.org) (Supplementary Tables SII and SIV). Additionally, in the
SA samples, eight miRNAs were significantly overexpressed (fold-
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were underexpressed (fold-change decrease range: 1.13–1000; >2-
fold-decrease n = 25) (Table II) when compared with Nz controls.
Four down-regulated miRNAs passed the FDR correction (P-value ≤
0.0006).
Among the differentially expressed miRNAs, 25 miRNAs were shared
among OA and SA groups, either down- (n = 23) or up-regulated (n =
2), when compared with Nz controls (Table II). Remarkably, among the
shared down-regulated miRNAs in azoospermia, there was no
expression value (Cp value > 38) for miR-202-3p, miR-202-5p, miR-383-
5p, miR-506-3p, miR-508-5p, miR-510-5p, miR-513a-3p, miR-513c-5p,
miR-514a-3p, miR-518e-3p, miR-520h, miR-521, miR-873-5p and miR-9-
3p (Supplementary Table SIV). Those exosomal miRNAs that presented
statistically lower levels in both OA and SA men were candidates for hav-
ing preferentially been derived from the testicular cells associated with
presence of the germline (n = 23), whereas the 19 miRNAs found to be
down-regulated in OA but not in SA samples are suggested to be prefer-
entially secreted by somatic cells of the testis and/or the epididymis
(Table II). Interestingly, among the latter group of miRNAs we found sev-
eral that were described to be epididymis-specific, such as the X-linked
miR-888 cluster (Li et al., 2010; Belleannee et al., 2012).
ExosomemiRNA levels in SP identify
azoospermia with different origins
Subsequently, we compared the miRNA expression profile of SP exo-
somes between SA and OA-V samples with potential implications for
diagnosis. We found that 12 miRNAs (Fig. 2) presented significant differ-
ences in expression between groups, although no miRNA passed the FDR
correction. According to this profiling outcome, we proceeded to validate
several miRNAs as candidate biomarkers of the origin of azoospermia.
First, five miRNAs (miR-182-3p, miR-205-5p, miR-31-5p, miR-539-
5p, miR-941) were selected for validation in a larger number of indivi-
duals based on the following criteria: we selected those miRNAs that
presented ≥1.7-fold difference in expression between groups and a
Cp value <34 in any of the azoospermic groups (Fig. 2). We included
in the validation stage of the study three additional miRNAs, such as
miR-122-5p, miR-34c-5p, miR-449a, that we found were differentially
expressed in SP exosomes between azoospermic and Nz individuals
(Table II) and were previously described as being preferentially pro-
duced from the meiotic and/or post-meiotic germ-cell stages of the
testis (Yu et al., 2005; Bouhallier et al., 2010; Bao et al., 2012).
Additionally, the cellular content of all these three miRNAs was found
to be decreased in testicular developing germ-cells and in mature
sperm from patients with deficient sperm production; and the combin-
ation of the expression values of these three miRNAs in testicular
biopsies is able to predict the availability of sperm in the biopsy for
ART (Muñoz et al., 2015). PiRNAs are sncRNAs predominantly
expressed in the germline. Thus, the piR-58527 (piRNABank accession
DQ591415) was additionally included in the validation study as it is
specifically expressed in the postmeotic germ cells (Heyn et al., 2012).
In order to determine the expression level of each miRNA in the dif-
ferent organs of the reproductive tract, the expression of the eight
Figure 1 Flow chart outlining the two stages of miRNA profiling and validation performed in the study. The number of microRNAs (miRNAs) and
individuals analysed at each stage are depicted. Nz, normozoospermia; SA, secretory azoospermia; OA-V, obstructive azoospermia from men success-
fully vasectomized; piRNA, Piwi-interacting RNA; RT-qPCR, quantitative RT-PCR.












Table II Seminal exosome-derived miRNAs differentially expressed in OA and/or SA compared with Nz individuals.
Seminal plasma exosomal
miRNA expression
miRNA Location Nz OA SA Deduced
miRNA origin
from our work
HumanmiRNA expression profile in
tissues
A. Underexpressed miRNAs
hsa-miR-202-3p chr. 10 1 0.001** 0.001** Testis T (Hu et al., 2014)
hsa-miR-514a-3p2cX chr. X 1 0.001** 0.001** Testis T (Hu et al., 2014)
hsa-miR-202-5p chr. 10 1 0.004** 0.004** Testis T (Hu et al., 2014); Sertoli cell expressed
hsa-miR-509-3-5p1cX chr. X 1 0.004** 0.016* Testis T (Hu et al., 2014)
hsa-miR-510-5p2cX chr. X 1 0.008** 0.008** Testis
hsa-miR-513c-5p3cX chr. X 1 0.010** 0.009** Testis
hsa-miR-518e-3p1c19 chr. 19 1 0.029** 0.080* Testis
hsa-miR-508-5p1cX chr. X 1 0.032** 0.031** Testis
hsa-miR-520h2c19 chr. 19 1 0.036** 0.054* Testis
hsa-miR-9-3p chr. 1, 5, 15 1 0.049** 0.047* Testis
hsa-miR-506-3p1cX chr. X 1 0.050** 0.047** Testis
hsa-miR-383-5p chr. 8 1 0.059** 0.057** Testis
hsa-miR-34c-5p chr. 11 1 0.059** 0.073* Testis T/EP (Hu et al., 2014)
hsa-miR-517c-3p2c19 chr. 19 1 0.069** 0.091* Testis
hsa-miR-873-5p chr. 9 1 0.082** 0.079** Testis
hsa-miR-34b-5p chr. 11 1 0.007* 0.167* Testis
hsa-miR-513a-3p1cX chr. X 1 0.036* 0.034* Testis
hsa-miR-5211c19.2c19 chr. 19 1 0.042* 0.040* Testis
hsa-miR-452-5p chr. X 1 0.063* 0.148* Testis
hsa-miR-122-5p chr. 18 1 0.094* 0.133* Testis
hsa-miR-449a chr. 5 1 0.237* 0.205** Testis
hsa-miR-499a-5p chr. 20 1 0.343* 0.315* Testis
hsa-miR-455-5p chr. 9 1 0.382* 0.297* Testis
hsa-miR-891b6cX chr. X 1 0.084* 0.455 Epididymis/Testis EP (Li et al., 2010, 2012; Hu et al., 2014)
hsa-miR-8906cX chr. X 1 0.090* 0.363 Epididymis/Testis EP (Li et al., 2010; Hu et al., 2014)
hsa-miR-34c-3p chr. 11 1 0.093* 0.382 Epididymis/Testis
hsa-miR-891a-5p chr. X 1 0.097* 0.448 Epididymis/Testis EP (Li et al., 2010, 2012; Hu et al., 2014)
hsa-miR-888-5p6cX chr. X 1 0.098* 0.391 Epididymis/Testis EP (Li et al., 2010; Hu et al., 2014)
hsa-miR-124-3p chr. 8, 20 1 0.101** 0.481 Epididymis/Testis
hsa-miR-892a6cX chr. X 1 0.107* 0.544 Epididymis/Testis EP (Li et al., 2010; Hu et al., 2014)
hsa-miR-551b-3p chr. 3 1 0.139** 0.246 Epididymis/Testis
hsa-miR-424-5p chr. X 1 0.212* 0.424 Epididymis/Testis T/EP (Hu et al., 2014)
hsa-miR-181b-5p chr. 1, 9 1 0.246* 0.362 Epididymis/Testis
hsa-miR-31-3p chr. 9 1 0.250* 0.367 Epididymis/Testis
hsa-miR-181a-5p chr. 1, 9 1 0.292* 0.459 Epididymis/Testis
hsa-miR-31-5p chr. 9 1 0.302* 0.548 Epididymis/Testis T/EP (Hu et al., 2014)
hsa-miR-10b-3p chr. 2 1 0.313* 0.923 Epididymis/Testis EP (Li et al., 2012)
hsa-miR-222-3p chr. X 1 0.323* 0.570 Epididymis/Testis Wide expression (Hu et al., 2014)
hsa-miR-455-3p chr. 9 1 0.364* 0.439 Epididymis/Testis
hsa-miR-205-5p chr. 1 1 0.367* 0.734 Epididymis/Testis
hsa-miR-182-3p chr. 7 1 0.399* 1.454 Epididymis/Testis EP (Li et al., 2012)
hsa-miR-95-3p chr. 4 1 0.678* 1.398 Epididymis/Testis
hsa-miR-9-5p chr. 1, 5, 15 1 0.342 0.328*
Continued
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miRNAs was first tested in testis, epididymis, prostate, SP and lympho-
cytes, the latter as external control cells (Supplementary Fig. S1). We
could corroborate the preferential testicular expression of miR-122-
5p, miR-34c-5p and miR-449a, whereas miR-205-5p is preferentially
expressed in epididymis and prostate. The miR-182-3p, miR-31-5p,
miR-539-5p and miR-941 are expressed in the three reproductive
organs (testis, epididymis and prostate).
Therefore, these particular eight miRNAs and one piRNA were indi-
vidually reanalysed in a subsequent set of semen samples (seven Nz
samples, 14 SA samples, 10 OA samples including five OA-V samples
and five OA-N samples, and three oligozoospermic samples) by RT-
qPCR (Fig. 1). First, our results showed that the expression values of
miR-122-5p (P < 0.0001), piR-58527 (P < 0.0001) and miR-539-5p
(P = 0.034) were statistically different between azoospermic and Nz
individuals (Supplementary Fig. S2). Interestingly, the miR-122-5p
expression value was statistically correlated with the concentration
of sperm in semen (r = 0.616, P < 0.0001).
Furthermore, when the SA and OA samples were compared, our
results show that the tendencies among the nine miRNAs/piRNA ana-
lysed were conserved among the two different approaches (miRNA
qPCR array and RT-qPCR; r: 0.93), although only two of them (miR-
205-5p, miR-31-5p; P < 0.004) as well as piR-58527 (P = 0.031) were
found to be statistically different between both groups of azoospermia
in the RT-qPCR validation analysis (Supplementary Fig. S2). The expres-
sion values of these three sncRNAs resulted in good predictive accuracy
[miR-205-5p (AUC 0.843, P = 0.005); miR-31-5p (AUC: 0.957; P <
0.0001); piR-58527 (AUC: 0.764; P = 0.030)] (Fig. 3A), suggesting they
have a potential use as indicators of the origin of the azoospermia. As a
comparison, the ROC curve analysis of blood FSH levels was also deter-
mined (AUC 0.850, P = 0.004). To determine if a multiplex model could
improve performance over single biomarkers for discriminating SA from
OA samples, the three previously selected miRNAs were analysed in a
multivariate logistic regression analysis. Interestingly, this analysis
resulted in a model that only included the miR-31-5p expression values.
The sensitivity and the specificity for predicting the origin of azoosper-
mia were 92.9 and 90%, respectively (Fig. 3B). Strikingly, an increased
value of sensitivity and specificity (100%) was obtained when FSH +
miR-31-5p values were included in the model.
When the OA sample group was divided into OA-N and OA-V






miRNA Location Nz OA SA Deduced
miRNA origin
from our work
HumanmiRNA expression profile in
tissues
hsa-miR-132-5p chr. 17 1 0.674 0.456*
hsa-miR-203a chr. 14 1 0.995 0.880*
B. Overexpressed miRNAs
hsa-miR-363-3p5cX chr. X 1 1.474** 1.241**
hsa-miR-365a-3p chr. 16 1 1.689* 1.394*
hsa-miR-29a-3p chr. 7 1 1.614* 1.288
hsa-miR-296-5p chr. 20 1 3.705* 2.400
hsa-miR-23b-5p chr. 9 1 2.590* 1.498
hsa-miR-21-3p chr. 17 1 2.202* 1.485
hsa-miR-193a-3p chr. 17 1 2.879* 1.783
hsa-miR-29c-3p chr. 1 1 1.687* 1.415 T/EP (Hu et al., 2014)
hsa-miR-361-3p chr. X 1 1.741* 1.575
hsa-miR-550a-5p chr. 7 1 2.465 9.455*
hsa-miR-423-5p chr. 17 1 1.129 1.485* T (Hu et al., 2014)
hsa-let-7f-1-3p chr. 9 1 1.093 1.808*
hsa-miR-153-3p chr. 2, 7 1 1.667 2.251*
hsa-miR-196b-3p chr. 7 1 1.123 1.451*
hsa-miR-96-5p chr. 7 1 1.750 1.694*
Statistically increased miRNA expression levels are depicted in green; statistically decreased miRNA expression levels are depicted in red
when compared with controls. Hsa, Homo sapiens.
*P < 0.05; ** P < 0.005.
1-6cX clusters in chromosome X.
1-2c19 clusters in chromosome 19.
T, preferential expression in the testis.
EP, preferentially expressed in epididymis.
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(P = 0.001); and miR-539-5p (P = 0.026)] were differentially
expressed between OA-N and SA samples whereas miR-31-5p and
miR-941 (P < 0.003) were down-regulated in OA-V compared with
SA samples. This observation suggests that the profile of exosomal
miRNA in semen is different in congenital obstruction of the genital
tract from that obtained from the vasectomy procedure, and probably
depends on the level at which the obstruction of the genital tract is
produced. We then specifically focused on the differences between
naturally occurring OA-N and SA samples. The expression values of
the three differentially expressed miRNAs resulted in good predictive
accuracy [miR-205-5p (AUC: 0.886, P = 0.012); miR-31-5p (AUC:
0.957; P = 0.003); miR-539-5p (AUC: 0.843; P = 0.026)], suggesting
they have a potential use as indicators of the origin of the congenital
azoospermia, as well as FSH (AUC: 0.843, P = 0.026). When the
multivariate regression analysis was performed, it resulted in a model
that, again, only included the miR-31-5p expression values. The sensi-
tivity and the specificity for predicting the origin of naturally occurring
azoospermia were 92.9 and 80%, respectively, confirming that exoso-
mal miR-31-5p expression values in semen samples could be useful to
predict the presence of a conserved spermatogenesis in the testis of
azoospermic individuals. Once again, an increased value of sensitivity
and specificity (100%) was obtained when (FSH + miR-31-5p) were
included in the predictive model.
ExosomemiRNA levels in SP and the
presence of intratubular mature germ cells in
spermatogenic disorders
In order to assess if SP miRNA expression and histological parameters
from a SA biopsy were associated and to know the physiological rele-
vance and/or the potential implications for reproductive treatments,
we compared the miRNA profile of four SA individuals (nos. 18–21)
with no spermatozoa in the testicular biopsy (Sp−) and eight SA sam-
ples (nos. 10–17) with presence of intra-testicular sperm (Sp+), the
latter including the samples from cryptozoospermic individuals and
those samples from individuals with a positive TESE value (>0.01 ×
106 sperm/ml) (Table I). The TESE value is defined as the number of
spermatozoa that was obtained directly after processing 100 mg of
biopsy in 1 ml of medium.
No significant differences between SA−(Sp+) and SA−(Sp−) were
found regarding the individual levels of the above eight miRNAs and
the piRNA in SP exosomes. However, when the multivariate regres-
sion analysis was performed, it resulted in a model that included the
miR-539-5p and the miR-941 expression values. Interestingly, the sen-
sitivity and the specificity for predicting the presence of spermatozoa
in a testicular biopsy were both 100% for the samples included in the
study. When FSH was incorporated in the regression analysis, the
model included miR-539-5p, miR-941 and FSH values resulting in true
positive and negative rates for predicting residual spermatogenesis in
the testes of again 100%.
Discussion
In the last decade multiple efforts have been made in order to develop
specific biomarkers to contribute in the diagnosis and prognosis of
male infertility and to increase the success of reproductive treatments.
At present, assessment of azoospermic patients is based on medical
history, physical findings, hormone analysis, karyotype and a limited
number of genetic tests. However, in some cases the diagnosis
remains elusive and testicular biopsy is necessary. Furthermore, even
in suspected non-obstructive azoospermia, currently available mar-
kers, such as elevated levels of FSH in blood or diminished testicular
volume among others, are unsatisfactory (Zitzmann et al., 2006;
Cissen et al., 2016), and thus testis biopsy is also mandatory to identify
men with some residual spermatogenesis. For these reasons, a non-
invasive screening test that could identify those individuals with real
chances of positive sperm recovery on the biopsy would be wel-
comed. Semen contains high concentrations of miRNAs, which can be
identified and quantified, making them candidates as biomarkers for
non-invasive diagnostic/prognostic purposes. Recently, a few studies
have focused on cell-free miRNAs from semen and found an associ-
ation between alterations of sperm quality and aberrant miRNA levels,
both in whole SP (Wang et al., 2011; Wu et al., 2012, 2013) and in
exosomes (Abu-Halima et al., 2016). In particular, miRNAs contained
in exosomes can reflect the pathophysiological conditions of the organ
of origin. These attributes support the idea that the study of exosomal
miRNA content could be useful as a specific indicator of alterations of
the organ/cells that released them.
First, in the present study we focused our attention on those
miRNAs that were statistically down-regulated both in OA-V and SA
individuals and identified 23 miRNAs associated with the presence of
the germline in the testis (Table II). Interestingly, three of these
miRNAs (miR-202-5p, miR-509-3-5p and miR-34c-5p) were previ-
ously described as being among the 10 most abundant miRNAs in
human testis (Yang et al., 2013) and some of these miRNAs, such as
miR-34c-5p, miR-449a and miR-122-5p, had been previously found to
be underexpressed in testicular and sperm samples with deficient




































# # # # #
Figure 2 Differential abundance profile of exosomal miRNAs as
assessed by quantitative RT-PCR arrays from OA-V and SA semen
samples. Normalized expression levels relative to the mean of the 50
stable miRNAs are shown. Significant differences between groups are
indicated: *P-value < 0.05; **P-value < 0.01 (Student’s t-test). Those
miRNAs selected for validation are indicated by a # symbol.
Hsa miRNA, Homo sapiensmiRNA
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results. Additionally, from our results we come to the conclusion that
19 miRNAs have a preferential somatic origin from testis and/or epi-
didymis (down-regulated in vasectomized but not in SA patients)
(Table II). Among them, there are members of the X-linked primate-
specific miR-888 cluster (i.e. miR-890, miR-891a, miR-891b, miR-
892a, miR-888) previously described to be epididymis-specific and to
play a determinant role in regulating physiological functions of this
organ, such as sperm maturation (Li et al., 2010) supporting the ver-
acity of our conclusion. About 37% of the azoospermic down-
regulated SP exosomal miRNAs were located on the X-chromosome
and most of them are placed in clusters (Table II). Many X-linked
miRNAs are preferentially or exclusively expressed in spermatogenic
cells (Ro et al., 2007). In line with this, other exosomal miRNAs
located in clusters additionally have their expression altered in azoo-
spermia, such as clusters of chromosome 19 and clusters miR-34b/c
and miR-449, which were previously found to be significantly reduced
in testis with severe maturation blockade of the germline (Muñoz
et al., 2015).
There have been previous studies that compared the miRNA finger-
print, but in whole semen, from vasectomized and Nz individuals as
well as secretory azoospermia and normozoospermia. A first study
(Hu et al., 2014) identified 61 miRNAs that presented lower levels in
semen from vasectomized men than in semen from Nz individuals.
The altered miRNA profile is quite different from the one that we
identified, and only 17 miRNAs were shared between the two studies
(Table II). Other studies reported an altered miRNA fingerprint from
SP in SA, although the profile is quite different from the one found in
our miRNA study with SP exosomes. Specifically only miR-34c-5p,
miR-122 were found markedly decreased in SA (Wang et al., 2011) in
agreement with our data, but miR-146b-5p, miR-181a, miR-374b,
miR-509-5p and miR-513a-5p (Wang et al., 2011), miR-19b and let-7a
(Wu et al., 2012), and miR-141, miR-429 and miR-7-1-3p (Wu et al.,
2013) were not found to be altered in our study. These data suggest
that the miRNA profile in whole semen is quite different to the one
contained in the seminal exosomes.
Specifically, we aimed to assess the potential of SP miRNAs con-
tained in exosomes as sensitive and specific biomarkers for selecting
those azoospermic individuals with real chances of obtaining sperm-
atozoa from the testicular biopsy, either by themselves or combined in
predictive models. To our knowledge, this is the first time that the
miRNA expression profile from semen exosomes has been compared
between azoospermic individuals of different origin: obstructive versus
secretory azoospermia. Our results suggest that miRNAs in exosomes
from SP are useful for establishing the origin of azoospermia and can
predict the presence of sperm in testicular tissue. In fact, the levels of
12 miRNAs in exosomes differed significantly between obstructive as
compared with secretory azoospermia when assessed by miRNA
qPCR arrays, profiling 623 human miRNAs. These results were
Variable AUC 95% CI p-value
miR-182-3p 0.741 0.540–0.942 0.071
miR-205-5p 0.838 0.685–0.990 0.004
miR-31-5p 0.963 0.898–1.027 0.000
miR-539-5p 0.650 0.425–0.875 0.206
miR-941 0.603 0.343–0.863 0.442
piR-58527 0.744 0.550–0.937 0.040
miR-122-5p 0.723 0.515–0.932 0.095
miR-34c-5p 0.750 0.517–0.983 0.061

















Figure 3 Predictive efficiency of miRNA variables for distinguishing SA from OA samples. (A) Receiver operating characteristic (ROC) curve analysis
showing the predictive efficiency of miRNA variables for distinguishing SA from OA samples at the validation stage. (B) ROC curve of miR-31-5p for
predictive classification of azoospermic samples into SA and OA sub-phenotypes at the validation stage.
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validated for nine miRNA/piRNA in a larger cohort of patients and
two of them (miR-205-5p, miR-31-5p), as well as the germ-cell specific
piR-58527, were confirmed to be significantly down-regulated in OA
compared with SA. Interestingly, a positive correlation with a strong
predictive accuracy between the individual expression values of these
three sncRNAs and the selection of OA samples was determined for
the first time, reaching very good diagnostic efficiency (AUC > 0.95)
for the miR-31-5p. What is more, the sensitivity and specificity of miR-
31-5p for predicting the origin of azoospermia were notable (92.9 and
90%, respectively, when comparing OA and SA samples; as well as
92.9 and 80%, respectively, when comparing congenital OA-N and SA
samples); therefore, the use of miR-31-5p has potential implications
for diagnosis. Additionally, the combination of the values of well-
described blood biochemical markers, such as FSH, with those
obtained from miR-31-5p in SP resulted in a better efficacy of the pre-
dictive model.
Our results additionally provide evidence that a logistic model com-
bining the expression values of miR-539-5p and miR-941 was able to
discriminate the presence or the absence of sperm in a testicular biopsy
with a spermatogenic disorder with a high diagnostic accuracy. As a next
step, further studies, with an independent second population involving a
larger number of samples, are needed to confirm our findings.
In summary, our study identified several miRNAs altered in SP exo-
somes that potentially provide information about the origin of azoosper-
mia and the spermatogenic reserve of the testis. We propose the
analysis of miR-31-5p, miR-539-5p and miR-941 in exosomes from SP in
patients with azoospermia. The first diagnostic step will consider the
expression of miR-31-5p in exosomes in combination with FSH concen-
tration in blood to distinguish those samples with an obstruction and
conserved spermatogenesis from samples with a spermatogenic dis-
order. For the latter samples, the levels of miR-539-5p and miR-941 will
be used to document the presence of residual sperm in the testis. Our
findings contribute to the search for the most valuable genetic markers
that are potentially useful as tools for predicting the presence of testicular
sperm.We show that SP biomarkers for azoospermia represent a prom-
ising alternative or an addition to traditional biomarkers. Such informa-
tion would be useful in the clinics, helping in the diagnosis of azoospermic
patients but also providing realistic information about the chances of tes-
ticular sperm retrieval in order to avoid unnecessary biopsies.
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Supplementary data are available at Human Reproduction online.
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